Dexter L6 System
Distalmotion SA · Decision date Jun 11, 2026
What did the FDA decide?
FDA records K260653 as a 510(k) premarket notification, with a decision dated Jun 11, 2026. The decision code SESE records a finding of substantial equivalence. This is a 510(k) clearance.
- Regulatory pathway
- 510(k) premarket notification
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Jun 11, 2026
Regulatory record facts
- Identifier
- K260653
- Regulatory pathway
- 510(k) premarket notification
- Applicant
- Distalmotion SA
- Product code
- SDD
- Decision code
- SESE
- Decision date
- Jun 11, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Electromechanical Surgical System Wherein The Surgeon Annd The User Interface Can Be In The Sterile Field.
- Applicant
- Distalmotion SA
- Product code
- SDD
- FDA device class
- 2
FDA decision timeline
K260653 received
Application receipt date recorded by FDA.
K260653 · FDA decision
SESE
Related devices and submissions
Explore the linked device profile
Other records with product code SDD
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
Dexter L6 SystemK261398 | Distalmotion SA | 510(k) clearance | Aug 11, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A 510(k) submission seeks a finding of substantial equivalence to a legally marketed device. A clearance and a PMA approval are different regulatory decisions.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Distalmotion SA
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- Epalinges
Sources and methodology
- Original FDA record: K260653
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records